CARBOGEN AMCIS Expands Operations in Bubendorf
BUBENDORF, Switzerland (May 31st, 2016) — CARBOGEN AMCIS, the Swiss-based company offering process development and manufacturing of Active Pharmaceutical Ingredient (API) to the pharmaceutical industry, has announced the extension of its operations in Bubendorf.
On May 26th, 2016, we (CARBOGEN AMCIS) have undersigned the acquisition of the land and buildings of GEA Pharma Systems AG in Bubendorf, Hauptstrasse 145. The acquisition close to our current headquarters will become effective on Jan. 1st, 2017.
Located on 5’200 m² of land, the 3360 m2 multi-story building is divided into laboratory, production, storage and office areas and provides a set of clean-room GMP compliant suites. We are planning modification work in order to adapt the building to our specific requirements and convert more of the facility into GMP operations areas.
“The immediate proximity to our current headquarters and our larger scale production site in Bubendorf, Switzerland, is ideal. It will allow us to significantly extend our laboratory capacity for highly potent development and small scale production as well as analytical support.” said Stephan Fritschi, Vice-President Operations at CARBOGEN AMCIS. “Operations are scheduled to expand into the new building in 2017”.
“In the last couple of years we have experienced a significant and continuous increase in customers’ demand for additional capacity, including demand for labs and small scale development.” said Mr Janmejay Vyas, Chairman of the Dishman Group of Companies. “This acquisition is targeted to support our business growth and company expansion. It will allow CARBOGEN AMCIS to keep its position as an industry leader and outsourcing partner for complex highly potent APIs and ADCs”.
“I am delighted that we are able to extend our operations in Bubendorf in order to fulfil our customer needs and their growing expectations.” Commented Mark Griffiths, Global CEO of CARBOGEN AMCIS and the Dishman Group. “Moreover, this facility will bring new opportunities to further enhance our capabilities and capacities. In the near future, the company plans to introduce a number of additional capabilities including, but not limited to, commercial manufacture of ADC’s and additional Cat 4 (ng OEL) development capacity. The new facility is closely located with our current CARBOGEN AMCIS Headquarters in Bubendorf and as such enables us to leverage the existing support network to the new site"
CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.
Dishman Pharmaceuticals and Chemicals Ltd (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. The Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.